The stock of Syndax Pharmaceuticals Inc (SNDX) has seen a 0.31% increase in the past week, with a -21.08% drop in the past month, and a -9.60% decrease in the past quarter. The volatility ratio for the week is 3.70%, and the volatility levels for the past 30 days are at 4.53% for SNDX. The simple moving average for the last 20 days is -10.60% for SNDX stock, with a simple moving average of -4.72% for the last 200 days.
Is It Worth Investing in Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Right Now?
The stock has a 36-month beta value of 0.94. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SNDX is 79.62M, and at present, short sellers hold a 10.79% of that float. On August 15, 2024, the average trading volume of SNDX was 1.10M shares.
SNDX) stock’s latest price update
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) has seen a decline in its stock price by -1.46 in relation to its previous close of 19.87. However, the company has experienced a 0.31% gain in its stock price over the last five trading sessions. prnewswire.com reported 2024-08-12 that – Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of patients with KMT2Ar AML and ALL (p-value = 0.0036) – – NDA filing for revumenib in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 – WALTHAM, Mass., Aug. 12, 2024 /PRNewswire/ — Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that data from the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, a first-in-class menin inhibitor, in adult and pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) have been published in the Journal of Clinical Oncology.
Analysts’ Opinion of SNDX
Many brokerage firms have already submitted their reports for SNDX stocks, with Jefferies repeating the rating for SNDX by listing it as a “Buy.” The predicted price for SNDX in the upcoming period, according to Jefferies is $37 based on the research report published on June 28, 2024 of the current year 2024.
Scotiabank, on the other hand, stated in their research note that they expect to see SNDX reach a price target of $23, previously predicting the price at $36. The rating they have provided for SNDX stocks is “Sector Perform” according to the report published on January 31st, 2024.
Mizuho gave a rating of “Buy” to SNDX, setting the target price at $45 in the report published on December 22nd of the previous year.
SNDX Trading at -7.51% from the 50-Day Moving Average
After a stumble in the market that brought SNDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.73% of loss for the given period.
Volatility was left at 4.53%, however, over the last 30 days, the volatility rate increased by 3.70%, as shares sank -17.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.45% upper at present.
During the last 5 trading sessions, SNDX rose by +0.31%, which changed the moving average for the period of 200-days by +54.54% in comparison to the 20-day moving average, which settled at $21.70. In addition, Syndax Pharmaceuticals Inc saw -9.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SNDX starting from Goldan Keith A., who purchase 1,250 shares at the price of $20.03 back on Jun 14 ’24. After this action, Goldan Keith A. now owns 52,623 shares of Syndax Pharmaceuticals Inc, valued at $25,037 using the latest closing price.
Stock Fundamentals for SNDX
Current profitability levels for the company are sitting at:
- -71.36 for the present operating margin
- 0.93 for the gross margin
The net margin for Syndax Pharmaceuticals Inc stands at -65.43. The total capital return value is set at -0.66. Equity return is now at value -63.30, with -58.15 for asset returns.
Based on Syndax Pharmaceuticals Inc (SNDX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -242.9. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -95996.67.
Currently, EBITDA for the company is -229.94 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 387.0. The receivables turnover for the company is 0.37for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.50.
Conclusion
To sum up, Syndax Pharmaceuticals Inc (SNDX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
